@cornetjam7
Active 1 year, 3 months ago
A heightened risk of adverse events (AEs) was linked to the concurrent use of abacavir/dolutegravir/lamivudine and concomitant medications for other health conditions in patients. The combination therapy of abacavir/dolutegravir/lamivudine exhibited potent anti-HIV-1 activity, with 961% of patients demonstrating suppression of plasma HIV-1 RNA […] View
-
Hunt McCormack posted an update 1 year, 3 months ago
A heightened risk of adverse events (AEs) was linked to the concurrent use of abacavir/dolutegravir/lamivudine and concomitant medications for other health conditions in patients. The combination therapy of abacavir/dolutegravir/lamivudine exhibited potent anti-HIV-1 activity, with 961% of patients demonstrating suppression of plasma HIV-1 RNA to…[Read more]
-
Hunt McCormack became a registered member 1 year, 4 months ago
